Amylin agonists Market Outlook 2026–2034: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines amylin agonists, drugs that act on the amylin receptor to reduce appetite and slow gastric emptying, alone or combined with GLP-1 drugs. It tests how fast amylin based programmes extend beyond the weight loss achieved with GLP-1 drugs alone, and which participants capture value among developers, large pharmaceutical firms, peptide manufacturers and payers.

The first regulatory test is imminent. Novo Nordisk filed CagriSema, a fixed combination of cagrilintide and semaglutide, with the FDA on 18 December 2025 and expects a decision in the fourth quarter of 2026 with a full US launch at the start of 2027. In the REDEFINE 1 trial weight loss was 20.4% against 3.0% on placebo at 68 weeks, or 22.7% if all participants stayed on treatment. The conclusion is that the combination reaches weight loss well above semaglutide alone, which was 16.1% in the same trial.

The comparison with tirzepatide is mixed. In the REDEFINE 4 trial in February 2026, CagriSema did not meet its non-inferiority endpoint against tirzepatide 15 mg, with weight loss of 20.2% against 23.6% at 84 weeks. In September 2026, Novo reported that CagriSema at a lower dose beat tirzepatide 5 mg on weight loss at week 60, 12.4% against 9.1%, in the REIMAGINE 5 trial in type 2 diabetes. The conclusion is that amylin combinations are competitive with tirzepatide at lower doses but not yet at its highest dose.

Other amylin programmes are advancing. Eli Lilly reported Phase 2 weight loss of 9.5% to 20.1% with eloralintide in 263 adults at 48 weeks, against 0.4% on placebo, and has started Phase 3. Zealand Pharma and Roche reported 10.7% weight loss with petrelintide at week 42 against 1.7% on placebo, and Novo started Phase 3 of the single molecule zenagamtide in May 2026. Pfizer completed its acquisition of Metsera in November 2025 to add an amylin programme. The conclusion is that monotherapy results of about 10% to 20% position amylin as a tolerable complement to GLP-1 drugs, with the Phase 3 trials of 2027 and 2028 as the decisive data.

The brief treats amylin agonists as a high-impact category with an eight year horizon to 2034. It identifies which patients, regions and operators scale first and what each means for developers, large pharmaceutical firms, manufacturers and payers.

It is a focused 108-page decision brief for biopharma firms, payers and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which patients scale first and who captures value.

Amylin is a hormone released with insulin that lowers appetite and slows gastric emptying. Cagrilintide and petrelintide are long acting amylin analogues, and eloralintide is a selective amylin receptor agonist.

CagriSema combines cagrilintide with semaglutide in one weekly injection. Zenagamtide is a single peptide that acts on both the GLP-1 and amylin receptors.

Oral amylin agonists are in Phase 1, and the injectable Pfizer candidate has a reported half-life of 19 days that supports monthly dosing.

Uses are chronic weight management and type 2 diabetes, each under peptide drug regulation.

The limits are modest weight loss of monotherapy compared with combinations, nausea and dose limits, and competition from tirzepatide and other GLP-1 drugs. The period turns on whether amylin adds weight loss or tolerability that payers and prescribers will pay for.

The amylin agonists market, covering sales of approved amylin-based products, related licensing and collaboration revenue, and related peptide manufacturing and device services, is valued at USD 0.1–0.3 billion in 2026 and is projected to reach USD 6.98–20.93 billion by 2034, at a CAGR of 70%.

The 2026 base rests on early licensing and collaboration income and peptide manufacturing services, as no amylin based obesity drug is approved at the time of writing. Growth then follows the first FDA decision on CagriSema, Phase 3 results for monotherapy and co-agonists and the first launches.

The forecast is sensitive to the FDA decision, comparison with tirzepatide, payer coverage and peptide manufacturing capacity. Regionally, North America leads on filings, prescriptions and trials, Europe on research and manufacturing, and Asia-Pacific on CDMO capacity and fast following developers.

The base case assumes an FDA approval of CagriSema around the turn of 2027, Phase 3 data for amylin monotherapy and co-agonists in 2027 and 2028 and wider coverage, giving the inflection in 2030. An accelerated case assumes an early approval and strong Phase 3 weight loss for newer molecules, bringing the inflection to 2029 and lifting the 2034 value to the top of the range. A delayed case assumes an FDA delay or restricted label and weak tolerability data, holding growth at the bottom of the range.

Growth drivers

• Patients with limited response or intolerance to GLP-1 drugs.
• Phase 3 weight loss results for amylin combinations.
• Demand for weight maintenance after GLP-1 treatment.
• Extension to type 2 diabetes.

Enablers

• Venture funding and financing rounds.
• Biopharma licensing and partnerships.
• Public research funding.
• Peptide manufacturing capacity.

Restraints and barriers

• Modest weight loss of monotherapy compared with combinations.
• Competition from tirzepatide and other GLP-1 drugs.
• Nausea and dose limits.
• Cost and complexity of manufacture.

The direction of amylin agonists is set by the need for options beyond GLP-1 weight loss, regulation, new molecules and delivery systems, biopharma dealmaking and partnering, and manufacturing cost.

The key participants in amylin agonists include Novo Nordisk A/S, Eli Lilly and Company, Zealand Pharma A/S, F. Hoffmann-La Roche Ltd, Pfizer Inc., AstraZeneca PLC, AbbVie Inc., Amgen Inc., Structure Therapeutics Inc., Verdiva Bio Limited, Viking Therapeutics, Inc., Gubra A/S, Boehringer Ingelheim International GmbH, Jiangsu HengRui Medicine Co., Ltd., Sanofi, Bachem Holding AG, PolyPeptide Group AG, Samsung Biologics Co., Ltd., Lonza Group Ltd, CordenPharma International GmbH, UnitedHealth Group Incorporated, CVS Health Corporation, Elevance Health, Inc., The Cigna Group, Centers for Medicare & Medicaid Services, Institute for Clinical and Economic Review, American Diabetes Association, The Obesity Society, European Association for the Study of Diabetes, European Association for the Study of Obesity, Mayo Clinic, Massachusetts General Hospital, U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Health Canada, Pharmaceuticals and Medical Devices Agency, National Medical Products Administration, National Institute for Health and Care Excellence, International Council for Harmonisation and United States Pharmacopeia.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as amylin agonists mature.

Novo Nordisk leads with the first filing and the broadest set of programmes, Eli Lilly, Zealand Pharma with Roche, and Pfizer hold advanced monotherapy and early programmes, and AstraZeneca, AbbVie, Structure Therapeutics and Verdiva Bio are earlier, while peptide manufacturers, payers, clinical centres, regulators and standards bodies shape how fast amylin products reach patients. Competitive intensity is high in 2026 because GLP-1 and tirzepatide incumbents set the standard, and it rises as amylin products are approved.

Where value migrates.

In 2026 value sits with the GLP-1 and tirzepatide incumbents and with the developers that hold the first amylin filing and late-stage programmes. By 2030 it moves toward companies with several approved amylin products, because payers and prescribers choose products with proven tolerability and weight loss. By 2034 it settles in integrated incretin, amylin and manufacturing platforms and in CDMOs with peptide capacity at scale. Margins hold for products with a clear advantage in weight loss or tolerability and narrow for late followers.

The signals converge on a first decision and many Phase 3 starts. An amylin combination was filed in December 2025 and a decision is expected in the fourth quarter of 2026, monotherapy and co-agonist programmes reached Phase 3 in 2026, and large firms have bought or licensed programmes. Each signal supports growth, and comparison with tirzepatide at its highest dose was not met.

Structural limits show where progress could slow: modest monotherapy weight loss, nausea and dose limits, competition from tirzepatide and other GLP-1 drugs, and the cost of manufacture. The brief therefore tracks four indicators: the FDA decision, Phase 3 weight loss and tolerability data, payer coverage and peptide manufacturing capacity.

The CagriSema combination, then amylin monotherapy and co-agonists, then oral and monthly formats are the expected order of development.